Literature DB >> 10413563

Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome.

M A Bédard1, B Pillon, B Dubois, N Duchesne, H Masson, Y Agid.   

Abstract

Parkinson's Disease (PD) is often associated with a subcortico-frontal syndrome (SCFS) that is mainly characterized by executive dysfunctions. The complete biochemistry of these dysfunctions remain misunderstood. Most studies have focused on the well-known nigro-striatal dopaminergic degenerations of PD, but a more satisfying understanding of the SCFS has come from the study of the cholinergic systems. We present here two new experiments carried out with long-term and acute anticholinergic treatments in PD. In the first experiment, the effects of a 2-week treatment with trihexyphenidyl were compared to those observed under placebo on a neuropsychological battery. Results showed that anticholinergic-induced deficits in PD were exclusively concerned with executive functions. In the second experiment, the effects of an acute subclinical dose of scopolamine were compared between normal controls and PD patients who were devoid of cognitive deficit on a subset of executive tasks. Results indicates that PD patients but not normal controls developed a transient SCFS for the duration of the drug action. In contrast to other populations with cholinergic depletions-such as Alzheimer's disease-cholinergic blockade in PD exacerbates specifically the SCFS. Such a discrepancy between these two neuropsychological profiles are discussed in terms of the specificity of the underlying cholinergic lesions. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413563     DOI: 10.1006/brcg.1999.1083

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  14 in total

1.  Differential effects of M1 muscarinic receptor blockade and nicotinic receptor blockade in the dorsomedial striatum on response reversal learning.

Authors:  Arianna Tzavos; Jane Jih; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2004-09-23       Impact factor: 3.332

2.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

3.  Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; G M Constantine; Ch A Mathis; J G Davis; R Y Moore; S T Dekosky
Journal:  J Neurol       Date:  2005-09-02       Impact factor: 4.849

4.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

Review 5.  Paraphilias and paraphilic disorders in Parkinson's disease: A systematic review of the literature.

Authors:  Paolo Solla; Marco Bortolato; Antonino Cannas; Cesare Salvatore Mulas; Francesco Marrosu
Journal:  Mov Disord       Date:  2015-03-11       Impact factor: 10.338

Review 6.  Dementia with Lewy bodies.

Authors:  Tanis J Ferman; Bradley F Boeve
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

Review 7.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

Review 8.  Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Authors:  Nandakumar S Narayanan; Robert L Rodnitzky; Ergun Y Uc
Journal:  Rev Neurosci       Date:  2013       Impact factor: 4.353

9.  Anticholinergic Load and Nutritional Status in Older Individuals.

Authors:  E Kose; T Hirai; T Seki; N Yasuno
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

10.  Effects of transient focal inactivation of the basal ganglia in parkinsonian primates.

Authors:  Mark S Baron; Thomas Wichmann; Demin Ma; Mahlon R DeLong
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.